Category: News

Archive

Categories

Category Tags

409A valuation AI Medical Service AOT asset valuation Biotech firms Biotechgate Biotechgate Digital Partnering brain activity measuring breast cancer Cells clinical trial database Cold Ablation Robotguided Laser Osteotome cranio-maxillofacial surgery Cyrill Bätscher early digestive track cancer detection Ferring Pharmaceutical filming Fujieda Ayumi Funding future of life sciences Gergely Ivanyi German Biotech German Life Sciences GTAI Health Made in Germany Heartseed Inc. HelloPartnering in-licensing opportunities JPM San Francisco Kiyoshi Hasegawa life science database Lily MedTech Inc. medical image analysis NeU Corporation patrik frei product valuation RESI Rhine-Main-Neckar biotech SARS CoV 2 Shiho Azuma Tomohiro Tada valuation Valuation Experts XB-01 Yone Production Co Ltd

Socials Share

  • Launch of the Life Science Cluster Member Directory

    Venture Valuation

    May 2020. Zurich

    Biotechgate/Venture Valuation and The Life Science Cluster (TLSC) announce that they entered a mutual partnership last month. As per the agreement, Venture Valuation created a member directory that has already been implemented in the TLSC website. It features profiles of all the companies being TLSC members along with a map of the cluster and basic sector statistics.

    The Life Science Cluster was established in 2016 to provide a networking platform and support to life science companies, both based in Norway and internationally. It is open to biotech, pharma, and other healthcare companies as well as those whose activity is based on natural resources like the marine sector, agriculture and forestry.

    TLSC is the second Norwegian partner of Biotechgate/Venture Valuation. The company has already been in an active partnership with the Oslo Cancer Cluster for five years.

    The TLSC member directory is available for free at tlsc.no/member-profiles.

    ‘We have a very good experience in cooperation with Norwegian and Nordic in general, industry associations, and are very happy to have TLSC as a partner. Hopefully, we will contribute to the promotion of the cluster and also enrich our global database with information about the Norwegian industry’
    Dr. Patrik Frei, Venture Valuation CEO

    Venture Valuation AG – www.venturevaluation.com
    Venture Valuation specializes in independent, third-party assessment and valuation of biotechnology, pharma and med-tech companies. Services are provided in the form of independent Valuation Reports to entrepreneurs (seed to pre-IPO) and investors. With offices in Switzerland, Ireland, UK, Canada, USA and Asia, Venture Valuation has an experienced team of scientists and business professionals with expertise in finance, biotechnology, pharmaceutical and regulatory.

    Biotechgate – www.biotechgate.com
    Biotechgate is a business development database that contains over 55,000 high-quality profiles of life science companies which include company descriptions, contact information, product pipeline information, financing rounds, management details, and licencing deals. In 2019 a clinical trial database containing over 500,000 records was added to Biotechgate. The new database is integrated with registries around the world.

    The Life Science Cluster – www.tlsc.no
    The Life Science Cluster is a network for all companies and organizations for which the life sciences are key. This includes health and medicine where Norway’s advanced healthcare system forms a unique basis for the development of new technology. It also encompasses the marine sector, agriculture and forestry, where Norway has world leading industries based on Norway’s vast natural resources and strong research-based technology development.

    Download the press release

    Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?

  • Venture Valuation organizes free digital partnering event

    Venture Valuation

    Zurich, May 8th 2020

    Venture Valuation is organizing a virtual partnering event for biotech, pharmaceutical and medical technology companies from May 18 – 20. With the help of the matchmaking platform HelloPartnering other participants can be contacted and meetings arranged in advance. The basic participation is free of charge.

    Download the press release (English)

    Download the press release (German)

     

    More information and registration:
    Visit Biotechgate Digital Partnering »

  • Biotechgate announces the launch of a clinical trial database

    Venture Valuation

    Zurich, 25th March 2019

    Biotechgate announces the launch of a clinical trial database with more than 460,000 trial records. Clinical trial data is imported from more than 13 registries around the world and continuously updated and catalogued. Thanks to the use of newly developed smart software components, the data is presented in a well-structured and easily searchable format, with links to Biotechgate listed companies whenever possible.

    Download the press release

    Would you like to be notified about new articles, reports and other valuable content published by Venture Valuation?

  • Biotechgate, HEALTH MADE IN GERMANY and Germany Trade & Invest (GTAI) to map German Life Science Industry

    Venture Valuation

    Zurich/Berlin, January 2019;

    Venture Valuation entered into a partnership with HEALTH MADE IN GERMANY, the export promotion program for the German healthcare industry initiated by the German Federal Ministry for Economic Affairs and Energy. HEALTH MADE IN GERMANY is implemented by Germany Trade & Invest (GTAI), the country’s economic development agency.  It is Venture Valuation’s fourth partner in Germany, after BioDeutschland, BioVallley Deutschland, and Cluster Biotechnology North Rhine-Westphalia (BIO NRW).

    As per the partnership agreement, Venture Valuation created a directory of life science, MedTech and eHealth companies located in Germany. The directory is now integrated into the HEALTH MADE IN GERMANY’s website and is accessible for free at the address: www.exportinitiative-gesundheitswirtschaft.de/EIG/Navigation/EN/Company-Directory/company-directory.html.

    The company directory is part of Biotechgate, a global database developed and owned by Venture Valuation. Biotechgate lists around 52,000 life science companies and other organizations, including 3,500 based in Germany.

    ‘We are thrilled to partner with organizations like HEALTH MADE IN GERMANY and GTAI. Germany is one of the biggest life science markets in Europe, so the partnership significantly expands our network. We hope the database will enhance the global exposure of German companies’.

    Dr. Patrik Frei, Venture Valuation/Biotechgate CEO

    ‘Germany’s healthcare industry enjoys an excellent reputation worldwide. German medical technology, pharmaceuticals, digital healthcare solutions, and medical biotechnology are in demand around the globe. Our new online directory of more than 3,500 of the country’s healthcare companies is giving interested people everywhere one-click access to possible business partners here”.

    Kirsten Herrmann, HEALTH MADE IN GERMANY at Germany Trade and Invest (GTAI)

     

    About the partners:

    HEALTH MADE IN GERMANY – www.health-made-in-germany.com | Germany Trade & Invest (GTAI) – www.gtai.de

    HEALTH MADE IN GERMANY is the export initiative for the German healthcare industry. It supports international companies and organizations that are interested in establishing contact with potential German partners and suppliers. Set up by the German Federal Ministry for Economic Affairs and Energy (BMWi), the initiative bundles expert market intelligence for easy industry access.  The HEALTH MADE IN GERMANY initiative is implemented by Germany Trade & Invest, the economic development agency of the Federal Republic of Germany, on behalf of the BMWi.

    Venture Valuation AG – www.venturevaluation.com 
    Venture Valuation specializes in independent, third-party assessment and valuation of biotechnology, pharma and med-tech companies. Services are provided in the form of independent Valuation Reports to entrepreneurs (seed to pre-IPO) and investors. With offices in Switzerland, Ireland, UK, Canada, USA and Asia, Venture Valuation has an experienced team of scientists and business professionals with expertise in finance, biotechnology, pharmaceutical and regulatory.

    Biotechgate – www.biotechgate.com
    The Biotechgate Database is a property of Venture Valuation AG, Switzerland. Biotechgate is a global Life Sciences Database containing over 50,000 company profiles and licensing assets and providing the user with information on life science companies, licensing products, financing rounds as well as key data on management structures and technology platforms. It also contains a database of licensing deals and associated financial information on individual deals as well as an investor database.

     
    Would you like to be notified about new reports and other valuable content published by Venture Valuation?

  • Launch of a Directory of Life Sciences and Health Technologies companies with an exclusive database in Québec

    Launch of a Directory of Life Sciences and Health Technologies companies with an exclusive database in Québec

    Venture Valuation

    Zurich / Montréal, November 26, 2018

    As part of the ongoing commitment of Montréal InVivo to promote the economic development and growth of the life sciences and health technologies (LSHT) sector in Québec, Biotechgate, a company owned by Venture Valuation, and Montréal InVivo, the LSHT industrial cluster of the Montreal metropolitan area, announce a partnership to make available online a new Directory of Québec-based Life Sciences and Health Technologies companies. The online directory will make it easier to find business partners in Québec and will inform visitors about the strength of the life science ecosystem.

    This collaboration will also ensure international visibility of Québec companies since the database integrated in the Directory is also integrated within Biotechgate, a global database of life sciences companies and organizations, which includes more than 50,000 company profiles. Thanks to a comprehensive search form, it allows users to seek specific companies filtering by sector, product phase and many other categories. User-friendly Québec Life Sciences and Health Technologies directory includes more than 1000 profiles of companies active in the Healthtech, Biotech, Pharma or Medtech sector, all profiles of which being updated continuously. The platform is one of 30 country-specific life science databases, which in collaboration with regional organizations, are run and maintained by Venture Valuation.

    “We are very pleased to partner with Biotechgate which will allow us to enhance the visibility of our Québec companies for investors and potential partners by giving visitors easy and focused access to the actors of our vast network of Biotech, Pharma and Medtech companies. This exclusive Québec Life Sciences database is a perfect tool to promote our innovative life sciences sector.”
    Frank Béraud, CEO of Montréal InVivo

    “We are excited to have Montréal Invivo as a new partner for Biotechgate and strengthen our network in North America. Québec is a very important life sciences hub and a bridge to Europe.”
    Patrik Frei, CEO of Venture Valuation / Biotechgate

    About Biotechgate – www.biotechgate.com
    The Biotechgate Database is property of Venture Valuation AG, Switzerland. Biotechgate is a global Life Sciences Database containing over 50,000 company profiles and licensing assets and providing the user with information on life science companies, licensing products, financing rounds as well as key data on management structures and technology platforms. It also contains a database on licensing deals and associated financial information on individual deals as well as an investors database.

    About Venture Valuation AG – www.venturevaluation.com
    Venture Valuation specializes in independent, third-party assessment, valuation and monitoring of emerging high growth companies in industries such as biotechnology, med-tech and high-tech. Services are provided in the form of independent Valuation Reports to entrepreneurs (seed to pre-IPO) and investors. With offices in Switzerland, Ireland, UK, Canada, USA and Asia, Venture Valuation has an experienced team of scientists and business professionals with expertise in finance, biotechnology, pharmaceutical and high technology industries.

     About Montréal Invivo – www.montreal-invivo.com
    About Montréal InVivo – www.montreal-invivo.com Montréal InVivo is the brand name for the life sciences and health technologies (LSHT) cluster of the Montréal metropolitan area. The cluster comprises almost 600 organizations, including more than 150 research centres, 80 subsidiaries of world-class companies and more than 40,000 people employed in the sector. A wellspring of great ideas, the cluster includes four universities and ranks first in Canada for the number of research centres. Montréal InVivo is a non-profit economic development organization dedicated to the creation of wealth. Its activities are supported by funding from the Ministère de l’Économie, de la Science et de l’Innovation (MESI), the Secrétariat à la région métropolitaine reporting to the Ministère des Affaires municipales et de l’Occupation du territoire, the Communauté métropolitaine de Montréal (CMM), Canada Economic Development (CED) for the region of Québec and private and institutional sectors.

    Contacts:

    Venture Valuation, Switzerland
    Patrik Frei
    +41 (43) 321 86 60
    support@biotechgate.com

    Montréal InVivo
    Sabrina Bernier
    514.987.9387
    sbernier@montreal-invivo.com

     

  • The Launch of the BioAlberta Life Sciences Database

    The Launch of the BioAlberta Life Sciences Database

    Venture Valuation

    Zurich, Edmonton January 2018

    BioAlberta, a Canadian life sciences industry organization, has recently become a new business partner of Venture Valuation/Biotechgate. BioAlberta gathers a flourishing biotech community comprised of around 170 life sciences companies, government organizations, support service providers, and research & academic institutions, situated across the province.

    As per the partnership agreement, Venture Valuation provided BioAlberta with their proprietary database of Albertan companies and related life science organizations that is now integrated into the BioAlberta website.

    The database displays profiles of all the companies located in the province, as well as those listed in the global Biotechgate database. Additionally, members of BioAlberta are granted an extended profile.

    Besides company profiles, the industry statistics, such as the number of companies by sector, and a breakdown of the industry as a whole by subsector are displayed. Having a company listed on the database is free of charge, and it is possible to edit the content of the profile. Also, getting access to the database through the BioAlberta website doesn’t require a paid subscription.

    Venture Valuation CEO Dr. Patrik Frei said: ‘We are delighted to acquire another valuable partner in Canada. It will allow extending our knowledge about the industry in the country that has a particularly active life sciences market’.

    BioAlberta President and CEO Mel Wong said: ‘BioAlberta is pleased to be a partner with Venture Evaluation in making Biotechgate available to our members.  Access to an industry database has always been an important tool in the work of industry promotion, development, and advocacy.  We look forward to enhancing our support for the biotechnology industry through access to Biotechgate’.

    About partners:

    BioAlberta (www.bioalberta.com) is the central voice and organizing hub for the life sciences industry in Alberta. It is a private, not-for-profit industry association, representing Alberta’s growing life science sector. BioAlberta activity is focused in four key strategic areas: advocacy, promotion & marketing, industry development, and networking.

    Biotechgate (www.biotechgate.com) is a global business development database containing nearly 50,000 company profiles and providing the user with information on available licensing products, financing rounds, key management, technology platforms and more.

    Venture Valuation (www.venturevaluation.com) Venture Valuation VV AG is the owner of the Biotechgate Database. The company specializes in independent, third-party assessment, valuation, and monitoring of emerging high growth companies in industries such as biotechnology, med-tech, and high-tech

  • Life Sciences BC – New Canadian Partner for Venture Valuation/Biotechgate

    Life Sciences BC – New Canadian Partner for Venture Valuation/Biotechgate

    Venture Valuation

    Zurich/Vancouver January 2018

    Biotechgate/Venture Valuation announce entering a partnership with Life Sciences British Columbia, a Canadian non-profit organization. The goal of the partnership is to develop and run a database comprised of the life science companies situated in the province of British Columbia. The database will be integrated into the Life Sciences BC website (lifesciencesbc.ca) and access will be provided free of charge to all website users. The database will list all members and sponsors of the organization

    The British Columbia database will be a part of the global Biotechgate database that currently includes over 49,000 companies predominantly from the Biotech, Pharma, Medtech, and eHealth sectors. Additionally, it lists many relevant service providers, investors, media, and academic institutions, as well as non-profit and government organizations. The data is continuously updated by both the Biotechgate team and the listed companies themselves as all of the listed companies have access to the content of their profiles that allows them to contribute to the project. The database features advanced search options that will also be available in the local integration on the Life Science BC website.

    Dr. Patrik Frei, CEO of Venture Valuation said: ‘We hope to gain a better insight into the vibrant life sciences industry in British Columbia thanks to the cooperation with our new partner’

    Dr. Lesley Esford, President of Life Sciences BC said: ‘We are pleased to partner with Biotechgate and expect that this search service will support the needs of our broader community. When you are a small to medium size business, it can be difficult to connect with the best service providers; I’m certain adding the Biotechgate database, will be of overall benefit to our membership.’

    About us:

    Life Sciences British Columbia (lifesciencesbc.ca) is a non-profit, industry association which supports and represents the life science community of British Columbia through leadership, investment, advocacy, and promotion of our world-class life science community.

    Biotechgate (biotechgate.com) is a global business development database containing nearly 50,000 company profiles and providing the user with information on available licensing products, financing rounds, key management, technology platforms and more.

    Venture Valuation (venturevaluation.com) Venture Valuation VV AG is the owner of the Biotechgate Database. The company specializes in independent, third-party assessment, valuation, and monitoring of emerging high growth companies in industries such as biotechnology, med-tech, and high-tech.

     

     

  • Venture Valuations Biotechgate Collaborates with California Life Sciences Association (CLSA) to Connect California’s Life Sciences Sector

    Venture Valuations Biotechgate Collaborates with California Life Sciences Association (CLSA) to Connect California’s Life Sciences Sector

    Venture Valuation

    Zurich, Bay Area & San Diego, CA – August 2017 – California Life Sciences Association (CLSA), the premier public policy advocacy and business leadership trade association representing California’s life sciences industry, and Venture Valuations Biotechgate, a global Life Sciences database today announced their collaboration to create an in-depth member directory for CLSA as well as a unique, industry leading company directory for California.

    The new CLSA Member Directory will be found on the association’s website at www.califesciences.org/member-resources and will also be a part of the larger Biotechgate global life sciences database (www.biotechgate.com), which includes more than 45,000 company profiles. CLSA members will have access to enhanced features such as a comprehensive search function, detailed profiles and the ability to filter companies by sectors, indications, product phase, location, therapeutic focus and many other categories.  CLSA will also be able to showcase the cluster strength and key metrics of California’s life sciences sector.  Sara Radcliffe, President and CEO of California Life Sciences Association (CLSA) said: “As the life sciences advocacy and business leadership trade association for life sciences in California, CLSA is pleased to provide our members with the tools and data they need to gather the latest industry intelligence as well as connect and network with each other. This new collaboration with Venture Valuations Biotechgate enhances our member experience and delivers the quality resources California’s life sciences sector deserves.”

    Dr. Patrik Frei, CEO of Venture Valuation said: “Partnering with California Life Sciences Association (CLSA) is a tremendous step forward for Biotechgate. Because CLSA represents one of the key life sciences clusters worldwide, we are very happy to welcome California’s premier Biotech and Life Sciences hub into the Biotechgate network. In addition, we are pleased to connect CLSA through Biotechgate with our global partners such as AusBiotech, BioCat, BioDeutschland, BioHolland, BioSweden, BioTaiwan, BIOTECanada, BIO.NRW, Life Sciences Ontario, MediconValley, OBN, State of Maryland and many more.”


    The Biotechgate Database is the property of Venture Valuation AG, Switzerland. Biotechgate is a global life science database providing the user with information on life science companies, licensing products, financing rounds as well as key contact information on management It also contains a database on licensing deals and associated financial information on individual deals.

     

    About us: 

    Biotechgate (www.biotechgate.com)

    The Biotechgate Database is property of Venture Valuation AG, Switzerland. Biotechgate is a global Life Science Database containing over 70,000 assets, licensing product, financing and deal information and a unique life sciences investors’ directory.

     

    California Life Sciences Association (CLSA) (www.califesciences.org)
    California Life Sciences Association (CLSA) is California’s premier life sciences public policy and business leadership trade association. With offices in Sacramento, San Diego, South San Francisco, Los Angeles and Washington DC, CLSA works closely with industry, government, academia and others to shape public policy, improve access to innovative technologies and grow California’s life sciences economy. CLSA serves biotechnology, pharmaceutical, medical device and diagnostics companies, research universities and institutes, investors and service providers throughout the Golden State. CLSA was founded in 2015 when the Bay Area Bioscience Association (BayBio) and the California Healthcare Institute (CHI) merged. Visit CLSA at www.califesciences.org, and follow us on Twitter @CALifeSciences, Facebook, Instagram, LinkedIn and YouTube.

     

    Venture Valuation AG (www.venturevaluation.com)

    Venture Valuation specializes in independent, third party valuation of biotechnology, med-tech and biopharma companies. Services are provided in the form of independent Valuation Reports to entrepreneurs (seed to pre-IPO) and investors. With offices in Switzerland (Europe), Canada (North America) and Singapore (APAC), Venture Valuation has done over 500 valuation worldwide with its experienced team of scientists and business professionals.

     

    Media Contact:
    Will Zasadny                                                            Patrik Frei
    Director, Communications CLSA                             CEO Venture Valuation
    Wzasadny@califesciences.org                                contact@venturevaluation.com
    +1 619-961-8848                                                     +41 43 321 8660

  • New Record in Valuation of Life Sciences Companies and Products

    New Record in Valuation of Life Sciences Companies and Products

    Venture Valuation

    Zurich / Singapore / Boston, March 2017 – Venture Valuation is looking back to a new record year in terms of valuations.

    The past year has seen a new record number of valuations provided by Venture Valuation to its clients with 45 valuations in 2016 compared to 31 in 2015. Over the two year period, the Venture Valuation team have provided their valuation services in geographies spanning Asia, Europe, the USA and Canada, including in Hong Kong, China, India, Singapore, UK, Germany, Italy, Finland, Switzerland, Spain, France, Austria, Sweden, Belgium, and the Netherlands. Asia represented around 15%, Europe 70% and the USA 15% of all valuations.

    Venture Valuation offers company and individual product and asset valuations. Over the period, around 40% were whole company valuations and 60% valuations of individual products. Most of the valuations were used for fund-raising, M&A, and licensing deals, as well as for compliance reasons including fairness opinions for reverse mergers and other transactions.

    Of the therapeutic companies and product valuations, about 25% had the lead product/ were still in pre-clinical development, about 20% in phase II and around 33% had/ were products already on the market. The average value of a company was around USD 50m and the average product valuation was around USD 150m driven mostly by products already on the market.

    Clients of Venture Valuation were investors (58%) such as Pharma, corporate investors, venture capital investors, family offices, business angels and universities, and the companies themselves (42%).

    The life sciences sectors represented included therapeutic biotechnology, diagnostics, medtech, and other biotech such as agro, veterinarian, nutraceuticals, TCM, R&D services, healthtech and industrial biotech. Within the therapeutics sector, the diverse range of companies and products were focused on cancer, CNS, dermatology, haematology, gene therapy, anti-infectives, arthritis, pain and many others.

    The average company valuation took around 4 to 6 weeks to complete and the average product valuation around 2-3 weeks. With a staff of over 25 people combining business and sciences backgrounds in North America, Europe and Asia and with the in-house database Biotechgate, Venture Valuation is a global leader in valuation of biotech, medtech, diagnostics, and pharma companies.

    Dr. Patrik Frei, CEO of Venture Valuation / Biotechgate

    About us:

    Biotechgate (www.biotechgate.com)

    The Biotechgate Database is property of Venture Valuation AG, Switzerland. Biotechgate is a global Life Science Database containing over 44,000 company profiles and providing the user with information on life science companies, licensing products, financing rounds as well as key data on management structures and technology platforms. It also contains a database on licensing deals, associated financial information on individual deals and a unique life sciences investors database.

    Venture Valuation AG (www.venturevaluation.com)

    Venture Valuation specializes in independent, third party assessment, valuation and monitoring of emerging life sciences companies (biotechnology, med-tech and pharma). Services are provided in the form of independent Valuation Reports to entrepreneurs (seed to pre-IPO) and investors. With offices in Switzerland/Ireland/UK (Europe), USA/Canada (North America) and Singapore (APAC), Venture Valuation has an experienced team of scientists and business professionals with expertise in finance, biotechnology, pharmaceutical and high technology industries.

    For further information, please contact: Patrik Frei, CEO Venture Valuation, contact@venturevaluation.com

  • Life Sciences in Europe Report – Smart Site Selection

    Venture Valuation

    Zurich / Singapore, June 2016 – Venture Valuation together with KPMG and its new partner EuropaBio has released its third Report on “Site Selection for Life Sciences companies in Europe”. The report now also added additional countries including Denmark, Finland, Italy, Spain and Sweden. The report looks at the strength of Biotechnology, Medical Technology and Pharma.

    In response to this growing need of life sciences companies for comprehensive and unbiased information on various countries and their ability to host key value drivers, KPMG, in collaboration with Venture Valuation and EuropaBio has published its report “Site Selection for Life Sciences Companies in Europe” for the third time.

    As in past years, the report offers a comprehensive and unique overview of the various aspects relevant for smart site selection, such as size and specialization of the clusters, business-friendly legislation, macroeconomics and, naturally, the tax system. This combination of operational aspects and tax considerations gives life science companies a first insight into how their new or redesigned value chain could look from a location point of view.

    Life Sciences clusters in Europe
    According to the report, there are basically three types of European countries attractive to locate key value drivers of life science companies

    1. Countries with strong clusters of life science companies and an attractive tax and business environment.
    2. Countries that have significant clusters of life science companies in their jurisdictions, but lack the benefits of an attractive business environment.
    3. Countries which have attractive business and tax regimes without the support of a strong domestic biopharmaceutical industry.

     
    All three types of countries can offer appealing opportunities for hosting certain key value drivers of life science companies.

    “We are happy to have extended the report to include additional countries and also to have found a new partner in EuropaBio to help promote the European Biotechnology and Life Sciences industry. The Report also provides a comparison of the key European clusters with the BayArea to give an international benchmark. Using Biotechgate as a basis for the data collection is a big advantage, as it tracks over 40,000 companies and its assets / licensing opportunities worldwide.”
    Dr. Patrik Frei, CEO of Venture Valuation / Biotechgate, Singapore/Switzerland
     
    To download the report please click here »
     
    About us:

    Biotechgate (www.biotechgate.com)
    The Biotechgate Database is property of Venture Valuation AG, Switzerland. Biotechgate is a global Life Science Database containing over 40,000 company profiles and providing the user with information on life science companies, licensing products, financing rounds as well as key data on management structures and technology platforms. It also contains a database on licensing deals, associated financial information on individual deals and a unique life sciences investors database.
     
    Venture Valuation AG (www.venturevaluation.com)
    Venture Valuation specializes in independent, third party assessment, valuation and monitoring of emerging life sciences companies (biotechnology, med-tech and pharma). Services are provided in the form of independent Valuation Reports to entrepreneurs (seed to pre-IPO) and investors. With offices in Switzerland/Ireland/UK (Europe), USA/Canada (North America) and Singapore (APAC), Venture Valuation has an experienced team of scientists and business professionals with expertise in finance, biotechnology, pharmaceutical and high technology industries.

     For further information, please contact: Patrik Frei, CEO Venture Valuation, contact@venturevaluation.com